全文获取类型
收费全文 | 3257篇 |
免费 | 222篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 126篇 |
妇产科学 | 94篇 |
基础医学 | 527篇 |
口腔科学 | 36篇 |
临床医学 | 270篇 |
内科学 | 778篇 |
皮肤病学 | 80篇 |
神经病学 | 394篇 |
特种医学 | 86篇 |
外科学 | 318篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 209篇 |
眼科学 | 24篇 |
药学 | 224篇 |
中国医学 | 5篇 |
肿瘤学 | 290篇 |
出版年
2024年 | 5篇 |
2023年 | 44篇 |
2022年 | 110篇 |
2021年 | 144篇 |
2020年 | 100篇 |
2019年 | 123篇 |
2018年 | 112篇 |
2017年 | 96篇 |
2016年 | 106篇 |
2015年 | 122篇 |
2014年 | 166篇 |
2013年 | 186篇 |
2012年 | 300篇 |
2011年 | 293篇 |
2010年 | 148篇 |
2009年 | 136篇 |
2008年 | 249篇 |
2007年 | 203篇 |
2006年 | 167篇 |
2005年 | 183篇 |
2004年 | 133篇 |
2003年 | 117篇 |
2002年 | 78篇 |
2001年 | 14篇 |
2000年 | 10篇 |
1999年 | 11篇 |
1998年 | 14篇 |
1997年 | 13篇 |
1996年 | 17篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 11篇 |
1992年 | 13篇 |
1991年 | 9篇 |
1990年 | 3篇 |
1988年 | 6篇 |
1987年 | 5篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 1篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有3495条查询结果,搜索用时 15 毫秒
41.
B. Fuentes S. Amaro M. Alonso de Leciñana J.F. Arenillas O. Ayo-Martín M. Castellanos M. Freijo A. García-Pastor M. Gomis M. Gómez Choco E. López-Cancio P. Martínez Sánchez A. Morales E.J. Palacio-Portilla M. Rodríguez-Yáñez J. Roquer T. Segura J. Serena J. Vivancos-Mora 《Neurología (Barcelona, Spain)》2021,36(4):305-323
ObjectiveTo update the Spanish Society of Neurology's guidelines for stroke prevention in patients with type 2 diabetes or prediabetes, analysing the available evidence on the effect of metabolic control and the potential benefit of antidiabetic drugs with known vascular benefits in addition to conventional antidiabetic treatments in stroke prevention.DevelopmentPICO-type questions (Patient, Intervention, Comparison, Outcome) were developed to identify practical issues in the management of stroke patients and to establish specific recommendations for each of them. Subsequently, we conducted systematic reviews of the PubMed database and selected those randomised clinical trials evaluating stroke as an independent variable (primary or secondary). Finally, for each of the PICO questions we developed a meta-analysis to support the final recommendations.ConclusionsWhile there is no evidence that metabolic control reduces the risk of stroke, some families of antidiabetic drugs with vascular benefits have been shown to reduce these effects when added to conventional treatments, both in the field of primary prevention in patients presenting type 2 diabetes and high vascular risk or established atherosclerosis (GLP-1 agonists) and in secondary stroke prevention in patients with type 2 diabetes or prediabetes (pioglitazone). 相似文献
42.
Paola Stefanelli Antonino Bella Giorgio Fedele Serena Pancheri Pasqualina Leone Paola Vacca Arianna Neri Anna Carannante Cecilia Fazio Eleonora Benedetti Stefano Fiore Concetta Fabiani Maurizio Simmaco Iolanda Santino Maria Grazia Zuccali Giancarlo Bizzarri Rosa Magnoni Pier Paolo Benetollo Antonio Ferro 《Clinical microbiology and infection》2021,27(4):633.e1-633.e7
ObjectivesA seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy.MethodsAll citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables.ResultsA total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40–49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity.ConclusionsThe estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. 相似文献
43.
44.
45.
46.
47.
Gliddon et al. conducted a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy of the angiotensin-converting enzyme inhibitor quinapril for the management of vascular damage in systemic sclerosis (SSc). The trial comprised 213 patients with limited cutaneous SSc or Raynaud's phenomenon (mean age 54 years, 182 females) who were randomly assigned to receive 80 mg/day, or the maximum tolerated dose, of quinapril (n = 105) or placebo (n = 108) for 2-3 years. Patients were assessed every 3 months. The number of new ischemic digital ulcers was recorded as the primary end point, while the frequency of Raynaud's phenomenon episodes, skin score, health status, pulmonary artery pressure and treatments for ischemia were also monitored as secondary end points. There were no detectable differences between patients treated with quinapril and those receiving placebo; however, although no severe adverse effects were observed, patients taking quinapril experienced significantly more adverse effects. 相似文献
48.
Hypothalamitis: a diagnostic and therapeutic challenge 总被引:1,自引:0,他引:1
Antonio?BianchiEmail author Marilda?Mormando Francesco?Doglietto Linda?Tartaglione Serena?Piacentini Libero?Lauriola Giulio?Maira Laura?De Marinis 《Pituitary》2014,17(3):197-202
To report an unusual case of biopsy-proven autoimmune hypophysitis with predominant hypothalamic involvement associated with empty sella, panhypopituitarism, visual disturbances and antipituitary antibodies positivity. We present the history, physical findings, hormonal assay results, imaging, surgical findings and pathology at presentation, together with a 2-year follow-up. A literature review on the hypothalamic involvement of autoimmune hypophysitis with empty sella was performed. A 48-year-old woman presented with polyuria, polydipsia, asthenia, diarrhea and vomiting. The magnetic resonance imaging (MRI) revealed a clear suprasellar (hypothalamic) mass, while the pituitary gland appeared atrophic. Hormonal testing showed panhypopituitarism and hyperprolactinemia; visual field examination was normal. Pituitary serum antibodies were positive. Two months later an MRI documented a mild increase of the lesion. The patient underwent biopsy of the lesion via a transsphenoidal approach. Histological diagnosis was lymphocytic “hypothalamitis”. Despite 6 months of corticosteroid therapy, the patient developed bitemporal hemianopia and blurred vision, without radiological evidence of chiasm compression, suggesting autoimmune optic neuritis with uveitis. Immunosuppressive treatment with azathioprine was then instituted. Two months later, an MRI documented a striking reduction of the hypothalamic lesion and visual field examination showed a significant improvement. The lesion is stable at the 2-year follow-up. For the first time we demonstrated that “hypothalamitis” might be the possible evolution of an autoimmune hypophysitis, resulting in pituitary atrophy, secondary empty sella and panhypopituitarism. Although steroid treatment is advisable as a first line therapy, immunosuppressive therapy with azathioprine might be necessary to achieve disease control. 相似文献
49.
Luigi Sciarra Paolo Golia Andrea Natalizia Ermenegildo De Ruvo Serena Dottori Antonio Scarà Alessio Borrelli Lucia De Luca Marco Rebecchi Alessandro Fagagnini Alberto Bandini Fabrizio Guarracini Marcello Galvani Leonardo Calò 《Journal of interventional cardiac electrophysiology》2014,39(3):193-200
Introduction
Catheter ablation (CA) is an established therapy for atrial fibrillation (AF). The SmartTouch catheter (STc) provides information about catheter tip to tissue contact force (CF). The Surround Flow catheter (SFc) provides a uniform cooling of the tip during ablation. We sought to analyze the impact of STc and SFc on CA of paroxysmal AF in terms of feasibility and acute efficacy.Methods and results
Sixty-three patients (mean age 57.6?±?9.8 years, 53 males) with paroxysmal AF underwent pulmonary veins (PVs) antral isolation, by using standard ThermoCool catheter (TCc) in 21, STc in 21, and SFc in 21. Total procedural, fluoroscopy, and radiofrequency (RF) delivery times; percentage of persistently deconnected PVs after 30 min; and percentage of isolated PVs at the end of the procedure were measured. The use of both STc and SFc obtained a reduction of fluoroscopy time (TCc 34?±?18 min, STc 20?±?10 min, p?<?0.001; SFc 21?±?13 min, p?=?0.02 vs TCc) and RF time (TCc 41?±?13 min, STc 30?±?14 min, p?=?0.013; SFc 30?±?9 min, p?<?0.01 vs TCc). The use of STc resulted in a reduction of procedural time (TCc 181?±?53 min, STc 140?±?53 min, p?<?0.001; SFc 170?±?51 min, p?=?NS vs TCc). The percentage of isolated PVs was comparable between groups (TCc 96 % vs STc 98 % vs SFc 96 %; p?=?NS). The percentage of deconnected PVs at 30 min was lower in TCc (89 %) than in STc (95 %) and in SFc (95 %) group (p?<?0.05).Conclusions
Both STc and SFc allowed a simplification of CA of paroxysmal AF. In addition, they reduced early PVs reconnection.Condensed abstract
Sixty-three patients with paroxysmal AF underwent ablation by standard ThermoCool, SmartTouch, or Surround Flow catheter. Both the SmartTouch and the Surround Flow significantly reduced radiofrequency and fluoroscopy times, as well as pulmonary veins reconnection rate at 30 min. Moreover, the SmartTouch reduced overall duration of the procedure. 相似文献50.